LIPI-WATCH, a Belgian/Luxembourg survey on achievement of European atherosclerosis society lipid goals

Clinical Drug Investigation

Volumn 19, Issue 3, 2000, Pages 219-229

  Muls, E ^a,e   De Backer, G ^b   De Bacquer, D ^b   Brohet, M ^c   Heller, F ^d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d Centre Hospitalier Jolimont Lobbes   (Belgium)

^e UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; AGED; ARTICLE; ATHEROSCLEROSIS; BELGIUM; BODY MASS; CLINICAL TRIAL; FEMALE; GENDER; HEALTH SURVEY; HUMAN; LUXEMBOURG; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK;

EID: 0034119631     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200019030-00007     Document Type: Article

References (35)

1. 1. Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med 1992; 152: 1490-500
2. 2. Martin MJ, Hulley SB, Browner WS, et al. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361 662 men. Lancet 1986; 2: 933-6
3. 3. Chen Z, Peto R, Collins R, et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991; 303: 276-82
4. 4. Recommendations of the European Atherosclerosis Society prepared by the International Task Force for prevention of coronary heart disease: prevention of coronary heart disease. Scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis 1992; 2: 113-56
5. 5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) JAMA 1993; 269: 3015-23
6. 6. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998; 19: 1434-503
7. 7. EUROASPIRE A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997; 18: 1569-82
8. 8. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996; 100: 197-204
9. 9. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996; 100: 605-10
10. 10. Pearson TA, Laurona IM. Treatment success in patient subgroups in the Lipid Treatment Assessment Project (L-TAP). Circulation 1997; 96 Suppl. 8: A 361
11. 11. Pyörälä K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-31
12. 12. Steiner PM, Freidel J, Bremner WF, et al. Standardization of micromethods for plasma cholesterol, triglyceride and HDL cholesterol with the lipid research clinics' methodology. J Clin Chem Biochem 1981; 19 Suppl. 8: 850
13. 13. Rifal N, Warnick GR, McNamara JR, et al. Measurement of low-density-lipoprotein cholesterol in serum: a status report. Clin Chem 1992; 38: 150-232
14. 14. Aberg A, Bergstrand R, Johansson S, et al. Cessation of smoking after myocardial infarction. Effects on mortality after 10 years. Br Heart J 1983; 49: 416-22
15. 15. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish and fibre intakes on death and myocardial infarction; diet and reinfarction trial (DART). Lancet 1989; 2: 757-61
16. 16. de Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-Iinolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994; 343: 1454-9
17. 17. O' Connor GT, Buring JE, Yusuf S, et al. An overview of randomised trials of rehabilitation with exercise after myocardial infarction. Circulation 1989; 60: 234-44
18. 18. Fuster V, Giotto AM, Libby P, et al. 27th Bethesda Conference (Task Force 8). Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol 1996; 27: 1039-47
19. 19. Muls E, Autier P, Malbecq W. et al. Coronary disease risk factors and LDL cholesterol-lowering efficacy of fibrates and simvastatin. Clin Drug Invest 1997; 14: 98-108
20. 20. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
21. 21. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
22. 22. Scandinavian Simvastatin Survival Study Group: randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Sinivastatin Survival Study (4S). Lancet 1994; 344: 1383-9
23. 23. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57
24. 24. Downs JR, Clearfield M, Weiss S, et al. Primary prevention of acute coronay events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-622
25. 25. Sueta CA, Petkun WM, Hart PA, et al. Recommended management of hyperlipidemia and heart failure: Are we following the guidelines? Circulation 1997; 96 Suppl. 1: 1-66
26. 26. Muls E, Hofmans E, Droussin AM, et al. Sequential management of hypercholesterolemia with fibrate and simvastatin. The Belgian general practitioners' trial. Clin Drug Invest 1995; 9: 116-26
27. 27. Bertolini S, Bon GB, Camphell LM, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997; 13: 191-7
28. 28. Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, one year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997; 80: 39-44
29. 29. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15: 678-82
30. 30. Brown AS, Bakker Arkema RG, Yellen L, et al. Treating patients wilh documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 1998; 32: 665-72
31. 31. Shepherd J. International comparison of awareness and attitudes towards coronary risk factor reduction: The HELP study. Atherosclerosis 1998; 137: S117-S123
32. 32. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332: 1125-31
33. 33. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust I996; 164: 208-11
34. 34. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications. A cross national study. JAMA 1998; 279: 1458-62
35. 35. Furnham A. Overcoming the obstacles-the outsider's view. Atherosclerosis 1999; 147 Suppl. 1: S53-S56